MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

AbbVie Inc

Отворен

СекторЗдравеопазване

205.82 -1.74

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

205.62

Максимум

211.94

Ключови измерители

By Trading Economics

Приходи

-1.6B

-23M

Продажби

642M

15B

P/E

Средно за сектора

87.887

73.239

EPS

2.16

Дивидентна доходност

3.14

Марж на печалбата

-0.152

Служители

55,000

EBITDA

-4.4B

535M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+2.89% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.14%

3.06%

Следващи печалби

25.04.2025 г.

Следваща дата на дивидент

15.05.2025 г.

Следваща дата на екс-дивидент

15.04.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

35B

369B

Предишно отваряне

207.56

Предишно затваряне

205.82

Настроения в новините

By Acuity

24%

76%

55 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

AbbVie Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.02.2025 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

12.02.2025 г., 13:41 ч. UTC

Значими двигатели на пазара

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

31.01.2025 г., 13:28 ч. UTC

Печалби

AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges

14.03.2025 г., 09:30 ч. UTC

Топ новини

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3.03.2025 г., 15:04 ч. UTC

Придобивния, сливания и поглъщания

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6.02.2025 г., 13:25 ч. UTC

Топ новини
Печалби

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6.02.2025 г., 12:00 ч. UTC

Печалби

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

5.02.2025 г., 12:00 ч. UTC

Топ новини

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

31.01.2025 г., 15:50 ч. UTC

Топ новини
Печалби

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31.01.2025 г., 13:51 ч. UTC

Печалби

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate -- IBD

31.01.2025 г., 13:47 ч. UTC

Топ новини
Печалби

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31.01.2025 г., 13:24 ч. UTC

Пазарно говорене
Печалби

AbbVie Gets More Upbeat on Skyrizi, Rinvoq -- Market Talk

31.01.2025 г., 12:46 ч. UTC

Печалби

AbbVie's Stock Pops 4% After Earnings Beat Estimates And Company Offers Upbeat View Of 2025 -- MarketWatch

31.01.2025 г., 12:39 ч. UTC

Печалби

AbbVie 4Q Global Rinvoq Net Revenue $1.83B, Up 46.2% >ABBV

31.01.2025 г., 12:38 ч. UTC

Печалби

AbbVie: Expect 2025 Revenue to Exceed Previous Peak >ABBV

31.01.2025 г., 12:38 ч. UTC

Печалби

AbbVie Now Sees Aesthetics Delivering High-Single-Digit Compound Annual Revenue Growth From 2025-2029 >ABBV

31.01.2025 г., 12:37 ч. UTC

Печалби

AbbVie Raises 2027 Combined Sales Outlook for Skyrizi, Rinvoq to More Than $31B >ABBV

31.01.2025 г., 12:37 ч. UTC

Печалби

AbbVie Reaffirms Expectations for High-Single-Digit Compound Annual Revenue Growth Rate Through 2029 >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie: 4Q Revenue Rose 6.1% on Operational Basis >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q Loss $22M >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q U.S. HUMIRA Rev $1.25B >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.69B >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q Global Skyrizi Rev $3.78B >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q International HUMIRA Rev $436M >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q Adj EPS $2.16 >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie Sees FY Adj EPS $12.12-Adj EPS $12.32 >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q Loss/Shr 2c >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q Global IMBRUVICA Rev $848M >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q Rev $15.1B >ABBV

Сравнение с други в отрасъла

Ценова промяна

AbbVie Inc Прогноза

Ценова цел

By TipRanks

2.89% нагоре

12-месечна прогноза

Среден 215.57 USD  2.89%

Висок 240 USD

Нисък 190 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за AbbVie Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

16 ratings

12

Купи

4

Задържане

0

Продай

Техническа оценка

By Trading Central

201.34 / 209.52Подкрепа & съпротива

Краткосрочен план

Weak Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Weak Bullish Evidence

Настроение

By Acuity

55 / 386 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.